Neumora Therapeutics/$NMRA
1D1W1MYTD1Y5YMAX
Capital at risk
About Neumora Therapeutics
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
- Ticker
- $NMRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- Watertown, United States
- Website
- www.neumoratx.com
NMRA Metrics
BasicAdvanced
$156M
-
-$1.22
2.78
-
Price and volume
Market cap
$156M
Beta
2.78
52-week high
$3.65
52-week low
$0.83
Average daily volume
742K
Financial strength
Current ratio
4.496
Quick ratio
4.206
Long term debt to equity
1.189
Total debt to equity
1.196
Interest coverage (TTM)
-31.94%
Profitability
EBITDA (TTM)
-206.187
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-73.85%
Return on equity (TTM)
-187.11%
Valuation
Price to book
3.49
Price to tangible book (TTM)
3.49
Price to free cash flow (TTM)
-0.801
Free cash flow yield (TTM)
-124.90%
Free cash flow per share (TTM)
-1.038
Growth
Earnings per share change (TTM)
-21.88%
3-year earnings per share growth (CAGR)
-35.52%
Upcoming events
No upcoming events
NMRA News
AllArticlesVideos
Funds containing NMRA
AllUSDGBPEUR
Fund name | Fund size | $NMRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.